Shares of Amneal Pharmaceuticals Inc (NYSE:AMRX) have been given an average rating of “Hold” by the thirteen ratings firms that are currently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, four have given a hold recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $8.00.
AMRX has been the topic of several analyst reports. Royal Bank of Canada lowered shares of Amneal Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $11.00 to $6.00 in a report on Thursday, July 11th. BMO Capital Markets cut their price objective on shares of Amneal Pharmaceuticals from $6.00 to $5.00 and set a “market perform” rating on the stock in a report on Tuesday, August 6th. ValuEngine raised shares of Amneal Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, October 2nd. Guggenheim began coverage on shares of Amneal Pharmaceuticals in a research note on Thursday, September 12th. They issued a “sell” rating and a $2.50 target price for the company. Finally, SunTrust Banks reaffirmed a “buy” rating and issued a $5.00 target price on shares of Amneal Pharmaceuticals in a research note on Tuesday, August 6th.
In related news, Director Ted C. Nark acquired 50,000 shares of the stock in a transaction dated Wednesday, August 28th. The stock was bought at an average price of $2.39 per share, with a total value of $119,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder International Ltd Fosun acquired 1,642,300 shares of the stock in a transaction dated Monday, August 5th. The shares were bought at an average cost of $3.04 per share, with a total value of $4,992,592.00. The disclosure for this purchase can be found here. Insiders acquired 1,788,966 shares of company stock valued at $5,377,057 in the last ninety days. Insiders own 26.34% of the company’s stock.
Several hedge funds have recently modified their holdings of the company. Point72 Asset Management L.P. bought a new stake in Amneal Pharmaceuticals during the 2nd quarter valued at $23,772,000. BlackRock Inc. lifted its position in shares of Amneal Pharmaceuticals by 9.4% during the 2nd quarter. BlackRock Inc. now owns 6,394,923 shares of the company’s stock valued at $45,852,000 after buying an additional 549,217 shares in the last quarter. Marshall Wace LLP lifted its position in shares of Amneal Pharmaceuticals by 487.8% during the 1st quarter. Marshall Wace LLP now owns 492,275 shares of the company’s stock valued at $6,977,000 after buying an additional 408,533 shares in the last quarter. Nuveen Asset Management LLC purchased a new position in shares of Amneal Pharmaceuticals during the 2nd quarter valued at about $2,505,000. Finally, Assenagon Asset Management S.A. purchased a new position in shares of Amneal Pharmaceuticals during the 3rd quarter valued at about $971,000. 34.79% of the stock is owned by institutional investors.
NYSE AMRX traded down $0.03 during trading hours on Wednesday, hitting $2.96. The company’s stock had a trading volume of 829,180 shares, compared to its average volume of 1,454,901. The stock has a fifty day moving average of $3.03 and a 200 day moving average of $6.48. Amneal Pharmaceuticals has a twelve month low of $2.27 and a twelve month high of $21.22. The firm has a market capitalization of $904.75 million, a P/E ratio of 3.11, a PEG ratio of 0.85 and a beta of 1.51. The company has a quick ratio of 1.41, a current ratio of 2.17 and a debt-to-equity ratio of 3.66.
Amneal Pharmaceuticals (NYSE:AMRX) last announced its quarterly earnings data on Monday, August 5th. The company reported $0.09 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.14 by ($0.05). Amneal Pharmaceuticals had a negative net margin of 3.65% and a positive return on equity of 28.20%. The business had revenue of $404.60 million during the quarter, compared to analyst estimates of $420.12 million. During the same quarter in the prior year, the company earned $0.24 earnings per share. The company’s quarterly revenue was down 12.5% on a year-over-year basis. On average, analysts predict that Amneal Pharmaceuticals will post 0.51 earnings per share for the current year.
About Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Featured Story: Mutual Funds
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.